Apotex announced that the company has released its alpha-adrenergic receptor agonist brimonidine tartrate ophthalmic solution 0.1% in the United States.

“[OAG] impacts over 2.7 million Americans, and millions more have [OHT]. Bringing this product to market will make a real difference for these patients, who depend on this medicine to preserve their vision,” said Peter Hardwick, president of Apotex. “We’re excited to be able to offer this high-quality, cost-saving option to prescribers and patients across the country.”